A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT ID: NCT06680817
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
850 participants
OBSERVATIONAL
2025-02-05
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Faricimab for nAMD
This cohort will be divided into two sub-cohorts based on eye treatment history: anti-VEGF treatment naive and anti-VEGF pre-treated.
Faricimab
Faricimab will be administered as per local clinical practice and local labeling.
Cohort 2: Faricimab for DME
This cohort will be divided into two sub-cohorts based on eye treatment history: anti-VEGF treatment naive and anti-VEGF pre-treated.
Faricimab
Faricimab will be administered as per local clinical practice and local labeling.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Faricimab
Faricimab will be administered as per local clinical practice and local labeling.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients have received at least one faricimab treatment (the first dose) in the study eye
* Patients should have available data for visual acuity (VA) and Central Subfield Thickness (CST) for the Baseline level (i.e. examinations to be performed at the index date or within 4 months prior to it)
Exclusion Criteria
* Concomitant participation in any interventional clinical study
* Active ocular inflammation and/or suspected/active ocular infection in either eye
* Patients treated with faricimab who have and are currently participating in patient support programs (PSP) that are Market Research and Patient Support Programs (MAP) including Post Trial Access Programs (PTAP) and Compassionate Use Programs (CUP)
* Patients with non-ocular sight threatening disease which have an effect on the primary endpoint (e.g., apoplexia)
* Hypersensitivity to the active substance or any of the excipients of Vabysmo (as per label)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LKH-Univ.Klinikum Graz
Graz, , Austria
Medizinische Universität Innsbruck
Innsbruck, , Austria
Kepler Universitätskliniken GmbH - Med Campus III
Linz, , Austria
Medizinische Universitat Wien
Vienna, , Austria
Hanusch Krankenhaus
Vienna, , Austria
Multiprofile Hospital for Active Treatment Trimontium OOD Plovdiv;Ophthalmology
Plovdiv, , Bulgaria
Eye Medical Center St. Luka
Plovdiv, , Bulgaria
Eye Diseases Medical Center LUX OPTICS;ophthalmology
Sofia, , Bulgaria
Tokuda Hospital
Sofia, , Bulgaria
Medical Clinic Svetlina
Sofia, , Bulgaria
Ambulatory for Group Practice for Specialized Medical Care in Ophthalmology - Dr. Grupchevi OOD;Ophthalmology
Varna, , Bulgaria
Krajska nemocnice Liberec a.s.
Liberec, , Czechia
Klaudianova Nemocnice - Mlada Boleslav;Ophtalmology dpt
Mladá Boleslav, , Czechia
Fakultni nemocnice Olomouc
Olomouc, , Czechia
Faculty Hospital Ostrava
Ostrava, , Czechia
Ustredni vojenska nemocnice - Vojenska fakultni nemocnice Praha
Prague, , Czechia
Helsinki University Central Hospital
Helsinki, , Finland
Tampere University Hospital
Tampere, , Finland
General Hospital of Athens "Korgialeneio - Benakeio" Hellenic Red Cross
Athens, , Greece
University General Hospital of Heraklion
Heraklion, , Greece
University Hospital of Larissa
Larissa, , Greece
Papageorgiou General Hospital of Thessaloniki
Thessaloniki, , Greece
Erzsebet Furdo Gyogyaszati es Szurokozpont
Miskolc, , Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont
Pécs, , Hungary
Szegedi Tudományegyetem ÁOK
Szeged, , Hungary
Mater Private Hospital
Dublin, , Ireland
Institute of Eye Surgery
Waterford, , Ireland
Barzilai Medical Center
Ashkelon, , Israel
Shamir Medical Center Assaf Harofeh
Beer Jacob, , Israel
Soroka university medical center
Beersheba, , Israel
Carmel medical center
Haifa, , Israel
Shaare Zedek Medical Center
Jerusalem, , Israel
Pauls Stradins Clinical University hospital
Riga, , Latvia
Riga East Clinical University hospital Bikernieki
Riga, , Latvia
Latvian-American Eye Center
Riga, , Latvia
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, , Netherlands
ETZ Elisabeth
Tilburg, , Netherlands
NZOZ Specjalistyczna Poradnia Lekarska Adrian Wojciech Przystupa
Bielsk Podlaski, , Poland
Centrum Uslug Medycznych OKO-MED
Grudziądz, , Poland
USK Nr 2 im. WAM w Lodzi, Centralny Szpital Weteranow
Lodz, , Poland
Szpital Wojewodzki w Poznaniu
Poznan, , Poland
Pomorski Uniwersytet Medyczny
Szczecin, , Poland
Szpitale Pomorskie, Szpital Specjalistyczny im. F. Ceynowy
Wejherowo, , Poland
Szpital Uniwersytecki im. Karola Marcinkowskiego w Zielonej Górze
Zielona Góra, , Poland
Espaco Medico Coimbra
Coimbra, , Portugal
ULS Lisboa Ocidental - Hospital Egas Moniz
Lisbon, , Portugal
Hospital CUF Tejo
Lisbon, , Portugal
IMO - Instituto de Microcirurgia Ocular
Lisbon, , Portugal
Hospital de Sao Joao
Porto, , Portugal
Nemocnica s poliklinikou Trebišov, a.s.
Trebišov, , Slovakia
Fakultna nemocnica Trencin Ocna klinika
Trenčín, , Slovakia
Fakultna nemocnica Trnava
Trnava, , Slovakia
OFTAL s.r.o. Specializovana nemocnica v odbore oftalmologia Zvolen
Zvolen, , Slovakia
General Hospital Murska Sobota
Murska Sobota, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Reference Study ID Number: MR45586 https://forpatients.roche.com/
Role: CONTACT
Phone: 888-662-6728 (U.S. Only)
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MR45586
Identifier Type: -
Identifier Source: org_study_id